Connect with us

Media OutReach

Bora 3Q25 Delivers Renewed Profitability as Efficiency and Scale Improves

Published

on

Strategic realignment powering Bora’s dual-engine businesses model

HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third quarter of 2025.

Quarterly Business and Financial Highlights

  • Company reported quarterly basic EPS of NT$5.09, with a loss per share of NT$1.49 from discontinued operations. Operating income reached NT$1,063 million and net income for continued operations came in at NT$822 million, resulting in quarterly EBITDA of NT$1,283 million, well on track to reclaim 2023 core P&L indicators.
  • By the end of 3Q25, Bora’s operational integration and strategic streamlining efforts have been fully executed, meeting all targeted objectives. This milestone has led to a record-high CDMO business profitability, clear evidence that Bora’s dual-engine model is now entering its next phase of balanced but scalable growth.
  • Fueled by expanded capacity and the addition of new dosage forms, Bora’s CDMO business grew 56.5% year-to-date through 3Q25, reaching over NT$7.3 billion and returning to a sequential growth trajectory.
  • Pharma sales revenues fluctuated as legacy inventory phased out, and new products are still awaiting approvals. Generics portfolio competitiveness remains a key focus area in the near term. Led by Vigafyde, Bora’s rare disease portfolio continued to gain impressive market share with the vigabatrin franchise across three dosage forms continues. The Company targets to file its next specialty pharma product by year end to accelerate the rare neurology disease business. The Company also targets to market branded Deflazacort tablets by 2025 year end as a new driver for the business.
  • The Company expects NTD to remain in the range of NTD 30-31 per USD for its operational planning.
  • Share capital increased 19.99% during the quarter from stock dividend distribution, employee stock option exercise and convertible bond conversions.
  • The Board approved Level-1 ADR issuance with each ADR share corresponding to 1/5 common share and total ADR issuance <10% of outstanding shares to enhanced market trust and investor service.


Mr. Bobby Sheng, Chairman of Bora Group, stated, “Bora executed a record level of post-merger CAPEX investment in 2025 and we are progressing in line with our strategic plan. We have expanded our Maryland aseptic fill/finish capacity by approximately 10% while solid and liquid dosage capacity in Minneapolis and Mississauga grew around 3%. The investments allowed Bora to increase our operational efficiency and increase revenue per headcount in the CDMO business by ~30% during the quarter compared to beginning of the year.

The CDMO backlog rose to US$296 million, driven by 27 new contracts and over 20 new molecules year-to-date, providing solid visibility into 2026 with 72% commercialized projects. Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio, while paving the way for selective in-house manufacturing of specialty assets in the U.S.

As we look ahead, Bora is entering a phase of disciplined expansion and broader global recognition. Across our CDMO facilities in Asia and North America, we continue to actively navigate tariff and geopolitical challenges and turn them into new opportunities, strengthening supply chain resilience, and deepening collaboration with multinational partners.

On the pharma sales side, we continue to shed legacy low margin generics, increase our cashflow, and focus on our high-value generics pipeline, with certain PIV opportunities progressing to maturity in 2026. We remain dedicated on enhancing portfolio quality and increasing our Branded assets through selective specialty drugs, in order to build a more predictable and margin-accretive revenue base that mitigates product commoditization and price degredation.

In parallel, we are expanding our capital-market reach into the United States through the OTCQX Level-1 ADR program. We believe the Bora ADR will improve access and transparency for global institutional investors, while enabling overseas employees to participate in Bora’s growth. With no dilution and increasing visibility, we are laying the foundation for a stronger and more global 2026, defined by scaled growth, operational synergies, and increasing investor confidence.

3Q2025 Operational Achievements & Full Year Outlook


Global CDMO Operations

Global CDMO Operations (excluding intercompany orders from Upsher-Smith) revenues arrived at NT$1.78 billion in the third quarter and back to the sequential growth zone, representing approximately 37.13% of total revenue. A total of 418 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 33%. Year-to-date, CDMO revenues grew 18.98% over last year and reached NT$5.27 billion. Bora continues to execute on expanding this customer base to enhance business visibility and stability.

  • As the Company ramps up its Maple Grove site, the momentum for U.S. manufacturing has been encouraging. Several clinical-stage clients are now transitioning into long-term strategic partnerships, with project scale and client size both increasing. Maple Grove is well positioned to be the Center of Excellence for scale-up and U.S. supply-chain integration for Bora.
  • Large molecule CDMO operation revenues saw nearly 50% increase over the previous quarter, driven by one new ADC client and several change orders in addition to Cipla’s own labeled product launch under the collaboration agreement. Positioned as a one-stop CDMO platform alongside Bora Pharmaceuticals, Bora Biologics is now fully accelerating its CDMO operations

Pharma Sales Operations

Pharma Sales Operations in the third quarter reached a revenue of NT$3.02 billion, down 6.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 62.83% of total revenues.

  • Discontinued loss per share (from the closure of the Plymouth production area) reflected the clearance sale of higher-cost inventories from Upsher-Smith’s legacy generics and internal supply transfer delayed by regulatory hurdles. These inventory clearance sales are now nearing completion. The greater-than-expected pricing pressure across our low margin generics reinforces the need to accelerate Bora’s transition toward higher-value and Branded specialty pharma products.
  • The Vigabatrin franchise market share expansion continues with the “total patient” indicator seeing breakthrough in October.
  • Bora continues to focus on DEE (Developmental and Epileptic Encephalopathies), where legacy compounds fail to meet significant unmet needs. The market is poised for new NCE entrants, expanding the addressable opportunity to roughly US$10 billion over the next 3–5 years. Bora aims to capture this growth through a Ready-to-Use 505(b)(2) pipeline and branded generics.

Recent Investor Conference

Bora will host an English online earnings call at 8:00 p.m. Taiwan time on Nov. 13th, 2025, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:30 p.m. on Nov. 14th, 2025. Both events will cover the company’s Q3’25 financial and business results and outlook.

English Online Earnings Presentation Link: https://events.q4inc.com/attendee/477519089

Bora will participate in the JP Morgan Healthcare Conference in January in San Francisco. For 1:1 meetings with management, please contact your JP Morgan representative.

Bora 2025 Earnings Schedule
Q4 2025: Expected in the 2nd week of March 2026

Hashtag: #BoraPharmaceuticals

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, visit .

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

Media OutReach

Siam Piwat redefines global retail with NEXTOPIA, a future prototype where sustainability is a transformative force for business, people, and the planet

Published

on

BANGKOK, THAILAND – Media OutReach Newswire – 12 May 2026 – In a bold bid to reshape the future of retail, Siam Piwat Group has unveiled NEXTOPIA at its flagship Siam Paragon, the world’s first prototype for a global sustainability platform that turns eco-conscious living into an immersive, everyday experience.

Chief Executive Officer Chadatip Chutrakul introduced the project during The Economist’s 5th annual Sustainability Week Asia, recently held in Bangkok, positioning NEXTOPIA as more than a response to necessity but as a genuine driver of business leadership and vision.

The vision for the future of retail is built on three interconnected pillars: co-creation with founders and partners, collaboration with tenants and communities, and customers. Together, they redefine retail as a platform shaped by shared purpose, creativity, and participation. This extends to redefining customer relationships through trust, inspiring customers to visit more often, spend more time, and deepen engagement within our ecosystem.

2. NEXTOPIA (ECOTOPIA).jpg

“Sustainability is no longer optional,” Chutrakul said. “We must accelerate and make a bold move. Real, lasting impact is never created alone. It requires co-creation across industries, united by purpose, in a place that captures the world’s attention and inspires change for the greater good.”

Launched in November 2025, the 15,000-square-meter attraction at Siam Paragon, a global landmark that draws more than 200,000 visitors daily, including a significant share of international tourists aims to move sustainability “beyond awareness into joyful and engaging experiences in everyday life,” she added.

Developed with more than 50 partners, NEXTOPIA operates under the theme “Co-creating Communities for a Better World.” It features infrastructure contributions from companies including B.Grimm, SCG, Indorama and Kasikornbank, incorporating solar energy, sustainable materials, advanced water systems, and cooling and clean air technologies.

4. NEXTOPIA.jpg

The project has achieved zero waste to landfill, cut energy consumption by 47%, reduced water use by 34% and lowered carbon emissions from construction materials by 59%. Within a year, water savings are projected to be equivalent to the volume of an Olympic-sized swimming pool. Over two years, decarbonization efforts will deliver the environmental benefit of creating a vast urban park.

NEXTOPIA is Thailand’s first multi-tenant retail building to earn EDGE Advanced certification for resource efficiency and a two-star Fitwel rating. It also received the Best in Building Health Award 2026 from Fitwel, achieving top scores for its design and quality-of-life features.

Tenants must adhere to some 50 sustainability criteria covering waste management and value chain practices, with many exceeding standard industry benchmarks. Siam Piwat developed the framework over three years to help partners adopt sustainable practices quickly while cutting costs and unlocking new value.

Interactive elements at NEXTOPIA invite visitors to participate directly, with kinetic floors and bicycles that generate electricity for redeemable rewards, alongside exhibits featuring Thailand’s largest collection of recycled art, created by artists from waste collected nationwide. ECOTOPIA, the country’s biggest eco-store, stocks more than 110,000 sustainable products, many recycled or upcycled, sourced from around 300 Thai communities and small businesses.

The project has also brought together more than 30 local communities and global organizations, including the United Nations, World Food Programme, UNDP Biofin and WWF, to exchange knowledge and ideas.

More than a shopping destination, NEXTOPIA functions as a living laboratory for experimenting and exchanging ideas that retail and real estate developers worldwide could adapt. It marks a strategic evolution for Siam Piwat, transforming the company from a premier retail developer into what it describes as “a global sustainability platform” that links businesses, people and innovation.

This shift aligns with intensifying global pressure on companies to meet their sustainability commitments under the Paris Agreement, as brands and consumers increasingly demand verifiable environmental action.

With NEXTOPIA, Siam Piwat is betting that the future of retail lies not just in selling goods, but in creating spaces where sustainability feels tangible, measurable and above all inspiring.

Setting a new benchmark for co-created, revolutionary retail, NEXTOPIA offers a scalable model that delivers both business value and meaningful impact – one that can be adopted globally.

Hashtag: #SiamParagon #NEXTOPIA #Sustainability #PrototypeCity #NetZero #TheEconomist #SustainabilityWeekAsia

The issuer is solely responsible for the content of this announcement.

About Siam Piwat

Siam Piwat is a leading retail and real estate developer behind Bangkok’s most iconic destinations, including Siam Paragon, Siam Center, Siam Discovery, ICONSIAM, and Siam Premium Outlets Bangkok, globally recognized for pioneering experiential destinations.

For over six decades, Siam Piwat has been renowned for creating iconic destinations and world-class experiences, continuously redefining Bangkok’s retail landscape through award-winning developments that set new global benchmarks. Guided by creativity, innovation, and sustainability, the company continues to lead with a bold vision s that inspire, engage, and delight customers from around the world, while creating long-term value for society, businesses, and future generations.

Continue Reading

Media OutReach

DTAP Expands Access to Sexual Health Services with Two New Clinics in Holland Village and Clarke Quay

Published

on

SINGAPORE – Media OutReach Newswire – 13 May 2026 – DTAP, Singapore’s pioneering GP+ medical provider established in 2005, announced the opening of two new clinics – DTAP Clinic @ Holland Village, which officially opened on 29 Apr 2025, and DTAP Clinic @ Clarke Quay, which officially opened on 23 May 2025. The expansion strengthens access to general and sexual healthcare services, including STD tests, STD screening and HIV tests, within central lifestyle districts.

As healthcare-seeking behaviours continue to evolve, there has been a noticeable shift towards earlier and more proactive screening, especially for sexually transmitted infections (STIs) and HIV. Increasing public awareness of the importance of timely testing and treatment has driven demand for accessible, confidential care delivered in a professional clinical setting. The expansion into Holland Village and Clarke Quay reflects this shift, with both clinics designed to offer a comfortable and private environment that supports individuals in seeking care with confidence.

DTAP operates as a GP+ medical centre, bridging the gap between general practice and specialist care. Fully accredited for HIV and STD testing and treatment, its clinical protocols adhere to Singapore Ministry of Health (MOH) guidelines, covering the full continuum from screening and early detection through to treatment and long-term management. Beyond sexual health, DTAP also supports men’s and women’s health, weight management and mental health.

Clinics are staffed by experienced doctors — both male and female — who take a friendly, open and non-discriminatory approach, ensuring patients can seek care with confidence and discretion.

“This expansion builds on DTAP’s longstanding commitment to accessible and confidential care, with over 20 years of experience since 2005. We are seeing a clear shift towards more proactive health-seeking behaviour, particularly in sexual health, with more patients coming forward earlier for screening and testing, including for conditions that were previously under-discussed. This highlights the importance of timely detection and access to care, supported by a discreet, comfortable environment with experienced doctors who provide care in a respectful, open and non-discriminatory manner,” said Dr. Alan Tan, Chairman of DTAP Clinics.

DTAP Clinic @ Holland Village and DTAP Clinic @ Clarke Quay are now open to patients. For more information on services, visit https://dtapclinic.com/.

Hashtag: #DTAP

The issuer is solely responsible for the content of this announcement.

About DTAP

DTAP clinics offer GP+ medical services, bridging the gap between general practice and specialist care. Established in 2005, DTAP provides services that extend beyond regular GP offerings, with key focus areas including men’s health and women’s health, including sexual health, STD check, weight management and mental health. Through all life stages, DTAP aims to be a trusted healthcare partner in both general and sexual health.

Continue Reading

Media OutReach

TP’s AI-powered debt collection solution recovers up to 40% debt, improves efficiency and saves costs

Published

on

SINGAPORE – Media OutReach Newswire – 13 May 2026 – Global digital business services leader TP (ex-Teleperformance) today reported that its award-winning AI-powered collections solution, TP.ai FAB Collect, matched human-level customer satisfaction scores while delivering a 40% debt recovery rate in live client deployments.

Collections are emerging as a critical lever for both financial performance and customer retention. Regional institutions including the Asian Development Bank have identified digital transformation of financial services and credit infrastructure as a strategic priority across Asia, while rising consumer delinquencies are increasing pressure on banks to modernise servicing and collections operations.

However, debt collection remains one of banking’s most complex challenges, as lenders struggle to improve recovery rates without damaging customer relationships. AI-driven, human-supported debt collection models are emerging as a potential way forward to help lenders tackle rising credit risk and changing borrower behaviour. TP.ai FAB Collect is designed by training AI on decades of human collections expertise and deploying it where volume demands scale, so human advisors can focus on preserving customer relationships.

From Recovery to Relationship Management

TP.ai FAB Collect empowers lenders to operationalise more predictive, customer-centric engagement at scale, moving beyond traditional recovery models without adding friction to the customer experience. Built on TP’s proprietary TP.ai FAB (Foundational AI Backbone) framework, the solution integrates advanced analytics, AI-driven decisioning, and omnichannel engagement to improve recovery outcomes while maintaining compliance and customer trust.

“We trained our AI on 40 years of human collections expertise. Now it handles the first wave, so our human advisors can focus on the conversations that truly matter. TP.ai FAB Collect has produced results across debt recovery, promise-to-pay and overall customer satisfaction.” explains Assaf Tarnopolsky, TP’s Chief Business Development & Customer Officer, APAC.

When deployed by a leading financial institution, TP.ai FAB Collect’s AI agents achieved a customer satisfaction (CSAT) score that was slightly higher than human agents while also achieving a 40% debt recovery rate. At a leading telecommunications company, AI agents adapted outreach to customers based on local payment behaviour, achieving a 7%-point improvement in the pay-to-contact ratio compared to the human-only model. The solution also improved recovery performance over time while reducing collections costs by 40% compared to a human-only model.

TP.ai FAB Collect was recognised with a 2026 Artificial Intelligence Excellence Award by the Business Intelligence Group and was named Technology of the Year by the Excellence in Customer Service awards.

Hashtag: #TPAPAC #TPaiFAB


, a global leader in digital business services which consistently seeks to blend the best of advanced technology with human empathy to deliver enhanced customer care that is simpler, faster, and safer for the world’s biggest brands and their customers. The Group’s comprehensive, AI-powered service portfolio ranges from front office customer care to back-office functions, including operations consulting and high-value digital transformation services. It also offers a range of specialized services such as interpreting and localization, visa and consular services, and recruitment process outsourcing services. The teams of multilingual, inspired, and passionate experts and advisors, spread in close to 100 countries, as well as the Group’s local presence allows it to be a force of good in supporting communities, clients, and the environment.

For more information: .

Continue Reading

Trending